Back to news

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire•17/11/2026•16:30 ET
0

Key Highlights

  • ➤Arrowhead granted 196,885 restricted stock units to 203 new employees.
  • ➤Inducement grants vest annually over four years and sit outside shareholder-approved plans.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 22, 2026, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 203 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 196,885 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in